Flu Vaccine Licensure Depends On Adjuvant; Fall Vaccination Campaign Likely
Executive Summary
Efforts are under way to expedite H1N1 vaccine development for a potential voluntary vaccine campaign in the fall, but how registration of the vaccine is handled by FDA depends on whether or not an adjuvant is used
You may also be interested in...
BioCryst Stock Rises After White House Calls For Quicker Pace On Swine Flu Drugs
Two Phase III trials are planned for a flu antiviral this year, but the company could be asked to provide supplies for U.S. emergency stockpile before approval.
Two-Dose H1N1 Vaccination Might Be Optimal, But Would Stress Supply
An FDA panel said the H1N1 flu vaccine should be given in two doses when the probable vaccine campaign starts in the fall, but government officials at the meeting said there will not likely be enough vaccine available at that point to follow that advice
Two-Dose H1N1 Vaccination Might Be Optimal, But Would Stress Supply
An FDA panel said the H1N1 flu vaccine should be given in two doses when the probable vaccine campaign starts in the fall, but government officials at the meeting said there will not likely be enough vaccine available at that point to follow that advice